These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. New Injectable Drug for Type 2 Diabetes. Aschenbrenner DS Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319 [No Abstract] [Full Text] [Related]
10. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Forst T Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040 [TBL] [Abstract][Full Text] [Related]
11. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402 [TBL] [Abstract][Full Text] [Related]
12. [Not Available]. Salvador J; Gaztambide S Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835 [No Abstract] [Full Text] [Related]
13. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. Fernández-García JC; Colomo N; Tinahones FJ Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839 [TBL] [Abstract][Full Text] [Related]
14. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. Hanefeld M; Raccah D; Monnier L Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
16. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. Scott LJ Drugs; 2017 Aug; 77(12):1353-1362. PubMed ID: 28667587 [TBL] [Abstract][Full Text] [Related]
17. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Christensen M; Miossec P; Larsen BD; Werner U; Knop FK Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443 [TBL] [Abstract][Full Text] [Related]
18. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. Peterson SC; Barry AR Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990 [TBL] [Abstract][Full Text] [Related]
19. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Blumer I; Pettus JH; Santos Cavaiola T Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Raccah D; Miossec P; Esposito V; Niemoeller E; Cho M; Gerich J Diabetes Metab Res Rev; 2015 Feb; 31(2):204-11. PubMed ID: 25115916 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]